摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-5-methoxymethyl-pyrrolidin-2-one | 129624-79-9

中文名称
——
中文别名
——
英文名称
(S)-5-methoxymethyl-pyrrolidin-2-one
英文别名
S-5-methoxymethyl-2-pyrrolidone;(S)-5-(Methoxymethyl)pyrrolidin-2-one;(5S)-5-(methoxymethyl)pyrrolidin-2-one
(S)-5-methoxymethyl-pyrrolidin-2-one化学式
CAS
129624-79-9
化学式
C6H11NO2
mdl
——
分子量
129.159
InChiKey
UCZFSMMRBFRYHI-YFKPBYRVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    268.9±13.0 °C(Predicted)
  • 密度:
    1.031±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    (S)-5-methoxymethyl-pyrrolidin-2-one甲醇二氯甲烷 为溶剂, 反应 26.0h, 生成 (S)-5-Methoxymethyl-2-phenyl-2,5,6,7-tetrahydro-pyrrolo[2,1-c][1,2,4]triazol-4-ylium; chloride
    参考文献:
    名称:
    Knight, Roland L.; Leeper, Finian J., Journal of the Chemical Society. Perkin transactions I, 1998, # 12, p. 1891 - 1893
    摘要:
    DOI:
  • 作为产物:
    描述:
    (S)-5-(methoxymethyl)-1-(phenylmethyl)-2-pyrrolidinonesodium 作用下, 以 四氢呋喃 为溶剂, 反应 0.17h, 以56%的产率得到(S)-5-methoxymethyl-pyrrolidin-2-one
    参考文献:
    名称:
    焦谷氨酸衍生物的亲电氟化:底物依赖性反应性和非对映选择性在光学活性4-氟谷氨酸合成中的应用。
    摘要:
    作为合成4-氟代谷氨酸的单一立体异构体的方法,已经研究了对映体纯的2-(吡咯烷二酮)(4)的亲电氟化反应。衍生自9的内酰胺烯醇化物与NFSi的反应导致完全非对映选择性的单氟化反应,从而生成单环反式取代的α-氟内酰胺产物21。不幸的是,21和其他与结构相关的单氟化产物的动酸度降低,使得它们对A第二次氟化。相反,在描述的标准条件下,双环内酰胺12易于二氟化,以产生α,α-二氟内酰胺24。两种类型的相关内酰胺之间反应性的差异主要归因于用于去质子化的碱和存在于吡咯烷酮底物中的保护基之间的空间相互作用的存在或缺乏。基于对21的X射线晶体结构的分析,分子模型和实验证据得出了该结论。关键中间体21和24分别转化为(2S,4R)-4-氟谷氨酸和(2S)-4,4-二氟谷氨酸。
    DOI:
    10.1021/jo0106804
点击查看最新优质反应信息

文献信息

  • Pyrrolidone compounds for treating cerebral disorders
    申请人:Adir et Compagnie
    公开号:US05066651A1
    公开(公告)日:1991-11-19
    New pyrrolidone compounds of the formula: ##STR1## in which: R is OR", SR" or N (R.sub.3 R.sub.4) R' is optionally substituted alkyl or aryl, and the carbon in the 5-position of the pyrrolidone ring, which is substituted by CH.sub.2 R has the R or S configuration. These new compounds and their physiologically tolerable salts may be used therapeutically especially in the treatment of asthenias, ischaemic syndromes and nervous disorders associated with normal or pathological ageing.
    公式为:##STR1##其中:R为OR"、SR"或N(R.sub.3 R.sub.4);R'为可选择取代的烷基或芳基;以及吡咯烷酮环的5位碳原子由CH.sub.2取代,R为R或S构型。这些新化合物及其生理耐受盐可在治疗虚弱症、缺血综合征以及与正常或病理性衰老相关的神经紊乱中得到治疗。
  • [EN] AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS CYCLIQUES AROMATIQUES AZOTÉS À 6 CHAÎNONS ET LEUR UTILISATION
    申请人:MITSUBISHI TANABE PHARMA CORP
    公开号:WO2010030027A1
    公开(公告)日:2010-03-18
    The present invention provides aromatic nitrogen-containing 6-membered ring compounds having execellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I0] wherein: X1, X2 and X3 each independently are N or CH, and at least two of X1, X2 and X3 are N; A is *-CH=CH-, *-C(Alk)=CH-, *-CH2-CH2- or *-O-CH2- (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) -O-R2 wherein R2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R1 is not quinoxalinyl or quinolyl.
    本发明提供了具有出色的PDE10抑制活性的芳香氮含6元环化合物。本发明涉及以下式[I0]所代表的芳香氮含6元环化合物或其药学上可接受的盐,其制备方法,以及将所述化合物用作PDE10抑制剂,以及包含所述化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,并且至少两个X1、X2和X3为N;A为*-CH=CH-,*-C(Alk)=CH-,*-CH2-CH2-或*-O-CH2-(*为与R1的键);Alk为低碳烷基基团;环B为可选择取代的含氮脂肪杂环基团;R1为可选择取代的含氮杂环基团,其中的氮杂环基团为从喹喔啉基,喹啉基,异喹啉基,喹唑啉基,吡嗪基,嘧啶基中选取的基团,或者与其中的5至6元脂环融合的基团;Y0为从以下(1)到(5)组成的基团:(1)可选择取代的苯基或可选择取代的芳香单环5至6元杂环基团;(2)可选择取代的氨基羰基;(3)可选择取代的氨基低碳烷基;(4)-O-R2其中R2为氢,可选择取代的低碳烷基,低环烷基,脂肪单环5至6元杂环基团,或式[AA];(5)单取代或双取代氨基;但是,当Y0为单取代或双取代氨基时,R1的含氮杂环基团不是喹喔啉基或喹啉基。
  • AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE
    申请人:Morimoto Hiroshi
    公开号:US20110166135A1
    公开(公告)日:2011-07-07
    The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I 0 ] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I 0 ] wherein: X 1 , X 2 and X 3 each independently are N or CH, and at least two of X 1 , X 2 and X 3 are N; A is *—CH═CH—, *—C(Alk)=CH—, *—CH 2 —CH 2 — or *—O—CH 2 — (* is a bond with R 1 ); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R 1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y 0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) —O—R 2 wherein R 2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y 0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R 1 is not quinoxalinyl or quinolyl.
    本发明提供了具有优异的PDE10抑制活性的芳香族含氮6元环化合物。本发明涉及以下式[I0]或其药学上可接受的盐,其为一种芳香族含氮6元环化合物,以及其制备方法,用于PDE10抑制剂的化合物和包含该化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,且至少两个X1、X2和X3为N;A为*—CH═CH—、*—C(Alk)=CH—、*—CH2—CH2—或*—O—CH2—(*为R1的键);Alk为低碳基;环B为可选取代的含氮脂肪族杂环基;R1为可选取代的含氮杂环基,其中含氮杂环基是从喹啉基、喹啉基、异喹啉基、喹唑啉基、吡嗪基、嘧啶基和它们与5至6元脂环环融合的基中选择的基;Y0为从以下组合中选择的基(1)到(5):(1)可选取代的苯基或可选取代的芳香单环5至6元杂环基;(2)可选取代的氨基甲酰基;(3)可选取代的氨基低碳基;(4)—O—R2,其中R2为氢、可选取代的低碳基、低环烷基、脂肪单环5至6元杂环基或式[AA];(5)单取代或双取代的氨基;但当Y0为单取代或双取代的氨基时,R1的含氮杂环基不是喹啉基或喹啉基。
  • SYNTHESIS OF A NEW CHIRAL AMINE:(S)-5,5-DIMETHYL-2-METHOXYMETHYL-PYRROLIDINE
    作者:Leonardo J. Breña-Valle、Raymundo Cruz-Almanza、F. Oscar Guadarrama-Morales
    DOI:10.1081/scc-100103258
    日期:2001.1
    The title compound, a potential 'quat' auxiliary,was prepared from (S)-glutamic acid derivatives like (S)-N-Benzyl-5-methoxymethyl-2pyrrolidinone 1. Other routes starting from (S)-pyroglutamic acid in an attempt to bypass N-Aryl compounds like 1 were also tested, but. have not rendered the expected results yet.
  • US4999372A
    申请人:——
    公开号:US4999372A
    公开(公告)日:1991-03-12
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦